Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Lyra Therapeutics, Inc. (LYRA)

3.82   -0.07 (-1.8%) 11-28 10:02
Open: 3.82 Pre. Close: 3.89
High: 3.99 Low: 3.82
Volume: 8,203 Market Cap: 122(M)

Technical analysis

as of: 2022-11-28 10:50:28 AM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 5.16     One year: 5.89
Support: Support1: 3.4    Support2: 2.82
Resistance: Resistance1: 4.41    Resistance2: 5.05
Pivot: 3.92
Moving Average: MA(5): 3.84     MA(20): 4.13
MA(100): 5.35     MA(250): 5.09
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 26.3     %D(3): 27.3
RSI: RSI(14): 38.3
52-week: High: 8.18  Low: 3.29
Average Vol(K): 3-Month: 67 (K)  10-Days: 16 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ LYRA ] has closed above bottom band by 40.7%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.89 - 3.92 3.92 - 3.94
Low: 3.76 - 3.79 3.79 - 3.82
Close: 3.85 - 3.89 3.89 - 3.93

Company Description

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Headline News

Sun, 27 Nov 2022
Vivien Lyra Blair meets R2-KT - Fantha Tracks

Fri, 25 Nov 2022
How His Dark Materials Planned Ahead For A More 'Adult' Final Season For Dafne Keen And Amir Wilson As Lyra And Will - CinemaBlend

Fri, 25 Nov 2022
Scrypta (LYRA): Does it Score Poorly on Long-Term Trading Metrics Friday? - InvestorsObserver

Wed, 23 Nov 2022
Lyra: 'My ex gave me cooking gloves one year. What else can I say' - The Irish Times

Tue, 22 Nov 2022
Lyra, a Downtown Greek Hit, Spawns a Suburban Sibling - Eater Chicago

Mon, 21 Nov 2022
Dafne Keen, "Lyra Belaqua was a once in a lifetime role - Marie Claire UK

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -34 (M)
Shares Float 0 (M)
% Held by Insiders 3.183e+007 (%)
% Held by Institutions 1.093e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.941e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.29
Profit Margin (%) 0
Operating Margin (%) -3
Return on Assets (ttm) 375.7
Return on Equity (ttm) -36.6
Qtrly Rev. Growth 1.62e+006
Gross Profit (p.s.) -0.93
Sales Per Share 0.19
EBITDA (p.s.) -1.42
Qtrly Earnings Growth -5.367e+007
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 1.3
Price to Book value -1.17
Price to Sales 20.06
Price to Cash Flow 0

Stock Dividends

Dividend 21840
Forward Dividend 36030
Dividend Yield 571728%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.